Sanara MedTech Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Sanara MedTech is de winst gegroeid met een gemiddeld jaarlijks percentage van 39.6%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 18.2%. De inkomsten zijn gegroeid met een gemiddelde van 30.1% per jaar.
Belangrijke informatie
39.59%
Groei van de winst
41.90%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.90% |
| Inkomstengroei | 30.07% |
| Rendement op eigen vermogen | -3.61% |
| Nettomarge | -0.26% |
| Laatste winstupdate | 30 Jun 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • Jul 31
SMTI: MiMedx Deal Will Frame Future Upside And Downside Risk
Sanara MedTech's analyst fair value estimate has been adjusted from $36.00 to $32.00. Analysts point to the announced $35 per share acquisition by MiMedx and expectations for ongoing product and access expansion as key factors behind the updated price framework.Analyse-artikel • Jul 30
Is There Now An Opportunity In Sanara MedTech Inc. (NASDAQ:SMTI)?
Sanara MedTech Inc. ( NASDAQ:SMTI ), might not be a large cap stock, but it saw a significant share price rise of 68...
Narratiefupdate • Jul 06
SMTI: Future Soft Tissue Share Gains Will Support Bullish Outlook
Sanara MedTech's updated analyst fair value estimate has moved from $46.00 to $36.00, with analysts pointing to expectations for revenue growth of about 14.3%, a profit margin assumption of about 4.4%, and a future P/E of about 57.6x as key drivers of the revised target. Analyst Commentary Bullish analysts see Sanara MedTech as a company with room to execute on its surgical wound and soft tissue product portfolio, with fair value expectations framed around the updated revenue growth, margin, and P/E assumptions.
Narratiefupdate • Jun 22
SMTI: Soft Tissue Share Gains And Portfolio Expansion Will Drive Future Upside
Sanara MedTech's updated analyst price target has edged up from about $34.00 to roughly $34.33 as analysts factor in expectations for higher revenue growth, a different profit margin profile and a higher future P/E, supported by recent bullish initiation reports highlighting potential from share gains, broader market access and portfolio expansion in surgical wound and soft tissue products. Analyst Commentary Recent research on Sanara MedTech points to a generally constructive view on the company, with analysts focusing on its role in surgical wound and soft tissue management and how that could influence future execution and valuation.Narratiefupdate • Jun 07
SMTI: Cost Effectiveness Data And Bullish Initiation Will Drive Future Upside
Analysts now see fair value for Sanara MedTech holding at $34.00, supported by research that frames the stock through a slightly lower discount rate, steady revenue growth and profit margin expectations, and a marginally adjusted future P/E outlook. What's in the News Sanara MedTech issued earnings guidance for the second quarter of 2026, with expected net revenue in a range of $28.5 million to $29.5 million, compared with net revenue of $25.8 million for the same quarter a year earlier.Narratiefupdate • May 21
SMTI: Cost Effectiveness Evidence Will Support Future Upside Under Bullish Initiation
Analysts have maintained their $34.00 price target on Sanara MedTech, pointing to slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that align with a recently initiated bullish view on the stock. Analyst Commentary Bullish Takeaways Bullish analysts point to the maintained US$34.00 target as consistent with their constructive view, seeing current assumptions on discount rate, revenue growth, profit margin and future P/E as reasonable within their framework.Narratiefupdate • May 03
SMTI: Bullish Initiation And Cost Effectiveness Evidence Will Support Future Upside
Analysts have reaffirmed a $34.00 price target for Sanara MedTech, citing a fresh bullish initiation that highlights the company’s long term growth potential and supports unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed US$34.00 target as supported by the current fair value framework, with assumptions on discount rate, revenue growth, profit margin, and future P/E kept intact.Narratiefupdate • Apr 19
SMTI: Bullish Coverage And Cost Effectiveness Study Will Support Future Upside
Analysts have reduced their price target on Sanara MedTech by $2 to $34. This reflects updated views on growth, profitability, and a higher assumed future P/E, following recent bullish Street initiation commentary.Narratiefupdate • Mar 21
SMTI: Surgical Economics And Higher Margins Will Support Future Upside
Analysts have lowered their price target for Sanara MedTech from $40 to $36, citing revised fair value estimates, along with updated assumptions for revenue growth, profit margins, the discount rate and future P/E multiples. What's in the News A peer-reviewed study in the Journal of Medical Economics evaluates CellerateRX Surgical Powder as an add-on to standard care in high risk spinal surgery.Narratiefupdate • Mar 05
SMTI: New Revenue Guidance And Surgical Pipeline Will Support Future Upside
Analysts have kept Sanara MedTech's fair value estimate steady at $40.00 per share, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E inputs that reflect fine tuning rather than a change in overall conviction. What's in the News Sanara MedTech issued new guidance for the fourth quarter of 2025, with expected net revenue between $27.2 million and $27.7 million.Narratiefupdate • Feb 19
SMTI: Surgical Portfolio And Guidance Will Support Future Upside Potential
Analysts have maintained their $40.00 price target for Sanara MedTech, citing only very small adjustments to assumptions such as discount rate, long term revenue growth, profit margin and future P/E that did not materially change their overall valuation view. What's in the News Issued revenue guidance for Q4 2025, with expected net revenue in a range of $27.2 million to $27.7 million and commentary on the impact of approximately $1.8 million of BIASURGE sales in Q4 2024 on year over year comparisons (Corporate Guidance).Narratiefupdate • Feb 04
SMTI: Core Surgical Focus Will Drive Future Upside Potential
Analysts have modestly adjusted their price target for Sanara MedTech to US$40.00. This reflects small updates to assumptions around discount rate, revenue growth, profit margin and future P/E that keep their overall valuation view essentially unchanged.Narratiefupdate • Jan 21
SMTI: Core Surgical Focus And Orthopedic Alliance Will Drive Future Upside Potential
Analysts have trimmed their price target on Sanara MedTech from US$41 to US$40, reflecting updated assumptions around profit margins and future P/E expectations while keeping the overall long term growth story intact. What's in the News BIASURGE Advanced Surgical Solution received an Innovative Technology contract from Vizient Inc., signaling unique product qualities recognized by hospital experts on Vizient's client led councils (Key Developments).Narratiefupdate • Jan 07
SMTI: Core Surgical Focus And Orthopedic Alliance Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Sanara MedTech steady at US$41.00. This reflects only small tweaks to their underlying assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock.Narratiefupdate • Dec 14
SMTI: Core Surgical Focus Will Drive Future Profit Expansion And Upside Potential
Analysts have raised their price target for Sanara MedTech to approximately $41.00 per share, reflecting slightly lower discount rate assumptions and a marginally improved outlook for the company’s long term valuation multiples. What's in the News Sanara MedTech and Biomimetic Innovations provided an update on their strategic alliance focused on advancing orthopedic solutions and commercial readiness for new products (Key Developments).Narratiefupdate • Nov 29
SMTI: Leadership Transition And Discontinued Operations Will Drive Profit Expansion Ahead
Analysts have reiterated their previous price target for Sanara MedTech at $41.00. They cite minimal changes in key financial assumptions and maintain a stable outlook for the company.Narratiefupdate • Nov 15
SMTI: Leadership Transition And Streamlined Operations Will Drive Profitability Expansion
Narrative Update on Sanara MedTech: Analyst Price Target Revision Analysts have lowered their price target for Sanara MedTech from $50.00 to $41.00, citing updated estimates for key valuation metrics and a moderation in projected revenue growth. What's in the News Sanara MedTech is discontinuing operations of Tissue Health Plus (THP) to improve operating efficiency and will reclassify THP as discontinued operations in financial statements.Analyse-artikel • Aug 13
Sanara MedTech Inc. (NASDAQ:SMTI) Doing What It Can To Lift Shares
With a median price-to-sales (or "P/S") ratio of close to 2.7x in the Medical Equipment industry in the United States...
Nieuw narratief • Mar 31
Tissue Health Plus And OsStic Will Expand Market Reach
Expansion in sales coverage and partnerships aims to boost product adoption, enhancing revenue in both new and existing markets.Seeking Alpha • Jan 30
Sanara MedTech: A Promising Growth Story At An Attractive Valuation
Summary Shares have risen nearly 15% since the company posted preliminary Q4 results, which showed revenue up by 45-48% year over year. While growth was boosted by one-off demand for its BIASURGE product, underlying growth was still strong at 37%. There remains a long runway for growth for its surgical products, with the potential for this to be augmented by other growth drivers, including inorganic opportunities. While the surgical segment is solidly profitable, overall profitability is depressed by losses in Sanara’s pre-commercialization segment. At 3 times revenue, I find the current valuation attractive, and hence I am assigning shares a Buy rating. Read the full article on Seeking AlphaAnalyse-artikel • Dec 19
Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • Nov 15
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results
Sanara MedTech Inc. ( NASDAQ:SMTI ) defied analyst predictions to release its quarterly results, which were ahead of...Analyse-artikel • Sep 05
Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump
Sanara MedTech Inc. ( NASDAQ:SMTI ) shares have had a really impressive month, gaining 28% after a shaky period...Analyse-artikel • Aug 14
Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • May 23
Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story
There wouldn't be many who think Sanara MedTech Inc.'s ( NASDAQ:SMTI ) price-to-sales (or "P/S") ratio of 3.8x is worth...Analyse-artikel • Nov 15
Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • May 22
Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)
You may think that with a price-to-sales (or "P/S") ratio of 5.8x Sanara MedTech Inc. ( NASDAQ:SMTI ) is a stock to...Analyse-artikel • Mar 22
Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results
Sanara MedTech Inc. ( NASDAQ:SMTI ) last week reported its latest annual results, which makes it a good time for...Opbrengsten en kosten
Opbrengsten en kosten
Hoe Sanara MedTech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 26 | 110 | 0 | 84 | 5 |
| 31 Mar 26 | 107 | 1 | 81 | 5 |
| 31 Dec 25 | 103 | 0 | 79 | 5 |
| 30 Sep 25 | 102 | 2 | 79 | 4 |
| 30 Jun 25 | 97 | 3 | 75 | 3 |
| 31 Mar 25 | 92 | -1 | 75 | 3 |
| 31 Dec 24 | 87 | -2 | 72 | 3 |
| 30 Sep 24 | 78 | -3 | 68 | 3 |
| 30 Jun 24 | 72 | -7 | 65 | 4 |
| 31 Mar 24 | 68 | -5 | 60 | 4 |
| 31 Dec 23 | 65 | -4 | 57 | 4 |
| 30 Sep 23 | 63 | -8 | 55 | 4 |
| 30 Jun 23 | 60 | -9 | 53 | 4 |
| 31 Mar 23 | 54 | -6 | 50 | 4 |
| 31 Dec 22 | 46 | -8 | 46 | 3 |
| 30 Sep 22 | 38 | -7 | 41 | 2 |
| 30 Jun 22 | 30 | -8 | 36 | 1 |
| 31 Mar 22 | 27 | -10 | 32 | 0 |
| 31 Dec 21 | 24 | -8 | 28 | 0 |
| 30 Sep 21 | 22 | -5 | 24 | 0 |
| 30 Jun 21 | 20 | -4 | 22 | 0 |
| 31 Mar 21 | 17 | -4 | 19 | 0 |
| 31 Dec 20 | 16 | -4 | 19 | 0 |
| 30 Sep 20 | 14 | -6 | 18 | 0 |
| 30 Jun 20 | 13 | -5 | 16 | 0 |
| 31 Mar 20 | 13 | -4 | 16 | 0 |
| 31 Dec 19 | 12 | -3 | 13 | 0 |
| 30 Sep 19 | 11 | -1 | 11 | 0 |
| 30 Jun 19 | 10 | 0 | 9 | 0 |
| 31 Mar 19 | 9 | 0 | 8 | 0 |
| 31 Dec 18 | 9 | 0 | 8 | 0 |
| 30 Sep 18 | 8 | 0 | 7 | 0 |
| 30 Jun 18 | 7 | 0 | 7 | 0 |
| 31 Mar 18 | 7 | 0 | 6 | 0 |
| 31 Dec 17 | 6 | 0 | 5 | 0 |
| 30 Sep 17 | 6 | 0 | 5 | 0 |
| 30 Jun 17 | 6 | 0 | 5 | 0 |
| 31 Mar 17 | 6 | -1 | 5 | 0 |
| 31 Dec 16 | 6 | -1 | 4 | 0 |
| 30 Sep 16 | 4 | -1 | 4 | 0 |
| 30 Jun 16 | 4 | -2 | 4 | 0 |
| 31 Mar 16 | 3 | -1 | 3 | 0 |
| 31 Dec 15 | 3 | -2 | 3 | 0 |
| 30 Sep 15 | 3 | -1 | 3 | 0 |
Kwaliteitswinsten: SMTI is momenteel verliesgevend.
Groeiende winstmarge: SMTI is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SMTI is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 39.6% per jaar verminderd.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van SMTI over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: SMTI is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 15.6% ).
Rendement op eigen vermogen
Hoge ROE: SMTI heeft een negatief Return on Equity ( -3.61% ), omdat het momenteel verliesgevend is.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/09 06:45 |
| Aandelenkoers aan het einde van de dag | 2026/09/09 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Sanara MedTech Inc. wordt gevolgd door 3 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Yi Chen | H.C. Wainwright & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |